By Karim Khaledi Histogenics Corp (NASDAQ:HSGX) was downgraded by Zacks from a “hold” rating to a “sell” rating in a report released on Thursday. Zacks’ analyst wrote, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The